News Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
3.72 ^USD	-1.59%		-4.37%	+40.38%

03-20	Sector Update: Health Care Stocks Ease Late Afternoon	MT
03-20	Sector Update: Health Care Stocks Down Wednesday Afternoon	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Ease Late Afternoon	03-20	MT
Sector Update: Health Care Stocks Down Wednesday Afternoon	03-20	MT
Design Therapeutics Stock Rises as RBC Says Q4 Results, Product Candidate Updates Show Progress	03-20	MT
Design Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results	03-19	GL
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-19	CI
North American Morning Briefing : Stock Futures -2-	03-19	DJ
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update	03-12	GL
Design Therapeutics, Inc.(NasdaqGS:DSGN) dropped from NASDAQ Biotechnology Index	12-15	CI
RBC Cuts Price Target on Design Therapeutics to $4 From $7 Amid Limited Near-Term Clinical Updates, Keeps Sector Perform, Speculative Risk	11-14	MT
Wedbush Trims Design Therapeutics' PT to $5 From $6, Says Waiting for 2024 Strategic Update; Maintains Neutral Rating	11-14	MT
Design Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024	11-13	GL
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	10/10/23	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	29/09/23	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	22/09/23	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	14/09/23	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	06/09/23	PR
Insider Buy: Design Therapeutics	31/08/23	MT
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	28/08/23	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Summary

Filters